ストックスクリーナーアプリを入手
2.13
0.95%
0.02
アフターアワーズ：
2.13
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene licensor Cellectis faces patent lawsuit in the U.S. - MSN
JP Morgan Upgrades Allogene Therapeutics (ALLO) - MSN
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN
Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance
10 Best Growth Stocks Under $10 to Invest In - Insider Monkey
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union
Allogene Therapeutics announces public offering of $175M of common stock - MSN
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat
[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey
Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India
Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates - Stocktwits
Allogene Therapeutics, Inc.Common Stock (NQ: ALLO - FinancialContent
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan
Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6%Should You Sell? - MarketBeat
Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus
Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia - marketscreener.com
Allogene expands lymphoma trial to South Korea, Australia - Investing.com
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
Allogene (NASDAQ: ALLO) proxy urges approval to raise authorized shares to 800M - Stock Titan
Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock - Legal Desire Media and Insights
Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy - Traders Union
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - The Manila Times
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene raises $200.4 million in stock offering By Investing.com - Investing.com India
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Sahm
ALLO Upgraded by JP Morgan -- Rating Changed to Neutral - GuruFocus
Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation - Traders Union
ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com
3.67%
大文字化:
|
ボリューム (24 時間):